Researchers discovered that 'hot pepper' receptors on the heart trigger symptoms of heart attack and may lead to new treatments for angina pectoris. The study found that these receptors cause blood vessels to constrict and increase blood pressure, leading to chest pain.
SourcePenn State·JournalThe Journal of Physiology·DateSep 1, 2003
A recent study found treating older adults with the flu to be cost-effective, while a Hong Kong-based SARS study reveals higher-than-expected mortality rates, highlighting the need for more effective diagnostic tools.
SourceAmerican College of Physicians·JournalAnnals of Internal Medicine·DateSep 1, 2003
Apple iPhone 17 Pro
Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.
A special section of BioScience provides in-depth analyses of assessment systems for protected area management effectiveness. Key findings include the need for more widespread use of assessments and monitoring, as well as the identification of critical management issues such as funding, staffing, and community relations.
SourceAmerican Institute of Biological Sciences·JournalBioScience·DateSep 1, 2003
A study published in the Proceedings of the National Academy of Sciences found that individuals with greater activity in the left side of the prefrontal cortex had a stronger immune response against disease. The researchers measured brain activity and immune function in 52 individuals between 57-60 years old, and found a positive corre...
SourceUniversity of Wisconsin-Madison·JournalProceedings of the National Academy of Sciences·DateSep 1, 2003
A new study by the American College of Physicians found that treating older adults with flu-like symptoms can be cost-effective, but preventing them through annual vaccinations is more beneficial. Vaccination decreases hospitalization needs and mortality rates, making it the best strategy for older adults.
SourceAmerican College of Physicians·JournalAnnals of Internal Medicine·DateSep 1, 2003
A new vaccine targets both the anthrax bacterium and its toxins, demonstrating improved effectiveness in mice tests. The dual-action approach also holds promise as a therapeutic vaccine to help those already infected control the bacteria over time.
SourceHarvard Medical School·JournalProceedings of the National Academy of Sciences·DateSep 1, 2003